Bronstein, Gewirtz and Grossman, LLC announces an investigation into Morphic Holding, Inc. and urges investors to contact the company!

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ:MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased and currently hold Morphic are encouraged to obtain additional information and assist in the investigation by visiting the firm’s website: bgandg.com/MORF.

Examination details

The investigation concerns whether Morphic’s board of directors breached its fiduciary duty and failed to provide relevant information to its shareholders prior to the merger.

Under the terms of the agreement, Morphic Holding shareholders will receive $57.00 in cash for each share they own.

What’s next?

If you are aware of facts related to this investigation or if you have purchased Morphic stock, you can assist this investigation by visiting the company’s website: bgandg.com/MORF. You may also contact Peretz Bronstein or his account representative Nathan Miller of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There are no costs for you

We represent investors in class action lawsuits on a contingency basis, meaning we ask the court to reimburse us for our expenses and attorney fees (usually a percentage of the total award) only if we win.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities fraud class action lawsuits and shareholder actions involving derivatives trading. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Past results do not guarantee similar results.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | (email protected)

SOURCE: Bronstein, Gewirtz & Grossman, LLC